How ‘October Theory’ could help you lose weight — and why it’s the month so many people go on GLP-1 drugs
Forget New Year’s resolutions — weight loss experts say the best time to slim down might actually be right now.
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
WEDNESDAY, Oct. 1, 2025 — People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according…
Weight-loss drugs ‘may lower cancer risk in those with obesity’
GLP-1 drugs, which include Ozempic, are widely prescribed in the US, first for type-2 diabetes and increasingly for weight management. (Reuters pic) ISTANBUL: Drugs like Ozempic and Wegovy, already popular for diabetes and weight loss, may also lower the risk of some cancers especially in women, according to a study by researchers at Indiana University […]
I’m losing a stone a month WITHOUT fat jabs & the game changer was a simple drinks swap that totally FREE
A MUM who lost four stone in four months has revealed exactly how she did it – and it’s got nothing to do with fat jabs. Abbie Lodge, 34, weighed 14st 7lbs at her heaviest, after turning to unhealthy eating habits following the births of her two children. Abbie Lodge weighed 14st 7lbs at her […]
Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions
Abstract Glucagon is a pancreatic peptide hormone whose receptor (GCGR) is expressed in the liver, kidney, and, to a lesser extent, various other tissues. Glucagon is well known as the counterpart to insulin in glucose homeostasis. However, recent evidence has revealed other potential roles of glucagon, which include the regulation of amino acid metabolism via […]
Oral Semaglutide Reduces CV, MALE in T2D Regardless of PAD
In a SOUL trial subanalysis, oral semaglutide lowers major adverse cardiovascular and limb events in type 2 diabetes patients with and without peripheral artery disease. Medscape Medical News
Danes probe cutting red tape in pharma package talks
Presented by EFPIA By GIEDRĖ PESECKYTĖ with CLAUDIA CHIAPPA, MARI ECCLES and RORY O’NEILL PRESENTED BY View in your browser or listen to audio SNEAK PEEK — The Danish Presidency of the Council of the EU is asking countries for “flexibilities” on the pharma legislation in talks with the European Parliament. — WHO members […]
Pfizer M&A prospect Metsera heads to phase III with lead GLP-1
Phase IIb data of Metsera Inc.’s lead GLP-1 receptor agonist, MET-097i, showed significant weight loss and good tolerability, supporting a phase III start later this year, and validating Pfizer Inc.’s decision a week ago to buy the obesity-focused company for $7.3 billion.
Proactive, personalized, equitable: NYC Health + Hospitals/Bellevue chief on the future of cardiac care
In August, all 11 hospitals within New York City-based NYC Health + Hospitals were recognized by the American Heart Association for providing quality cardiovascular and stroke care. Of those 11 hospitals, five received the association’s new Commitment to Quality award. The award recognizes hospitals that achieved silver level or higher in at least three of […]
‘Illegal Triple G’ fat jabs dubbed the ‘Godzilla’ of weight loss drugs flooding UK are ‘FAKE’, experts warn
ONLINE crooks are already trying to trick desperate Brits into buying the next big fat jab before it has even finished clinical trials, experts warn. Fake pharmacy websites are selling what they claim to be retatrutide, also known as Triple G or the “Godzilla” of weight loss injections. AlamyWeight loss jabs’ popularity has presented an […]